BONESUPPORT lifts 2025 sales and profit on robust U.S. growth

The latest update is out from BONESUPPORT HOLDING AB ( (SE:BONEX) ).

BONESUPPORT reported strong full-year 2025 growth driven by its U.S. business, with net sales up 31% to SEK 1.17 billion and U.S. segment sales rising 36%, while maintaining a gross margin of 92.6%. Adjusted operating profit increased to SEK 262 million and earnings per share improved slightly, underscoring the company’s ability to scale profitably.

In the fourth quarter, net sales rose 22% to SEK 312.5 million, supported by 24% growth in the U.S. and 13% in Europe and Rest of the World, though quarterly earnings per share declined year-on-year. The company also shifted its CERAMENT V bone infection application at the U.S. FDA from a 510(k) to a De Novo pathway and executed share swap measures to secure long-term incentive programs, moves that affect its regulatory timeline and capital structure management but leave its balance sheet with higher cash and net cash positions.

The most recent analyst rating on (SE:BONEX) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.

More about BONESUPPORT HOLDING AB

BONESUPPORT HOLDING AB is a medical technology company focused on orthobiologics, developing and selling bone graft substitutes such as its CERAMENT product line. The company operates primarily in the U.S. and Europe and the Rest of the World segments, targeting conditions including bone defects and infections with high-margin, specialized biomaterial solutions.

Average Trading Volume: 259,511

Technical Sentiment Signal: Hold

Current Market Cap: SEK11.66B

Learn more about BONEX stock on TipRanks’ Stock Analysis page.